Best stock investments – Eavesdropping on the Huddle at Zafgen

Best stock investments

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, choses his own topics, and his words and opinions are his own. You can see his latest comments and all of his past articles on his Gumshoe page, here.]

Investor ardor has cooled considerably for Zafgen ($ZFGN), a stock we first presented to readers as a long idea in February 2015 (“The Zed Files”).  But in October 2015, a tornado hit the sheepdip (“Is Zafgen Kaput?”), with disquieting insider sales surrounding early reports of death in beloranib-treated patients resulting from unanticipated thrombotic events (pulmonary embolism, for example). The saying of sooth led to further revelations of such episodes occurring outside the Prader-Willi syndrome (PWS) patient population. The unavoidable outcome of this was that the Food and Drug Administration placed the drug on clinical hold. Such action by the FDA is by no means universally fatal to a drug’s development, but places considerable onus on a drug company to revisit its data with extreme thoroughness, explain it, derive conclusions about whether …

Posted in Guest Articles
Tagged Atlas Venture, Cellceutix (CTIX), Deerfield Management, Esperion Therapeutics (ESPR), Fidelity Management |

– Best stock investments

Learn How To Be #1 on Google Results

Source link